When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case Report
- PMID: 29688923
- DOI: 10.1213/XAA.0000000000000775
When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case Report
Abstract
Angiotensin (AT) II is an endogenous hormone that acts on venous and arterial smooth muscle to cause vasoconstriction. Recent trials have sparked great interest in its ability to be used as a vasopressor for catecholamine-refractory hypotension. Herein, we describe the successful use of AT II in a patient with a colonic perforation with septic shock refractory to conventional treatment. After AT II initiation, there was an immediate reduction in catecholamine requirement, and the patient survived.
References
-
- Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous Angiotensin II for the Treatment of High-Output Shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534.
-
- Khanna A, English SW, Wang XS, et al.; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419430.
-
- Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension. 2001;38:12461249.
-
- Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663670.
-
- Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care. 2017;21:324.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources